



**Food and Drug Administration Advisory Committee Member  
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: A. Michael Lincoff, M.D.

Committee: Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC)

Meeting Date: January 10, 2018

I acknowledge that contingent upon public disclosure of the following financial interests related to the agenda item: New drug application (NDA) 208088 (oral testosterone undecanoate capsules) submitted by Lipocine Incorporated, for the proposed indication of testosterone replacement in males for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired), I may be considered for participation in the advisory committee meeting described above.

| <u>Type of Interest</u>             | <u>Nature</u>           | <u>Magnitude</u>                |
|-------------------------------------|-------------------------|---------------------------------|
| <b>I. Personal/Immediate Family</b> |                         |                                 |
| None.                               |                         |                                 |
| <b>II. Other Imputed Interests</b>  |                         |                                 |
| Employer's research contracts       | (b) (4), Competing firm | \$700,000 – \$750,000 total     |
|                                     | (b) (4), Competing firm | \$7,000,000 – \$7,500,000 total |

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

\_\_\_\_\_/S/\_\_\_\_\_  
Signature

\_\_\_\_12/14/2017\_\_\_\_\_  
Date